We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+4.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.49B
AUM Growth
+$287M
Cap. Flow
+$532M
Cap. Flow %
11.84%
Top 10 Hldgs %
50.53%
Holding
128
New
23
Increased
12
Reduced
25
Closed
8

Top Buys

Rank Stock Value
1
DSGN icon
Design Therapeutics
DSGN
+$173M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$75.9M
3
NVAX icon
Novavax
NVAX
+$49.8M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$43.3M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.5M

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$71.6M
2
VIE
Viela Bio, Inc. Common Stock
VIE
+$51.4M
3
IMVT icon
Immunovant
IMVT
+$32.3M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$30.6M
5
KURA icon
Kura Oncology
KURA
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 75%
2 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DTIL icon
101
Precision BioSciences
DTIL
$207M
$3.59M 0.08%
11,551
– –
EIGR
102
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.54M 0.08%
13,333
– –
KDMN
103
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.92M 0.07%
750,000
-100,000
-12% -$458K
ALLK
104
DELISTED
Allakos
ALLK
$2.87M 0.06%
25,000
-25,000
-50% -$3.16M
NUVB icon
105
Nuvation Bio
NUVB
$2.32B
$2.45M 0.05%
+234,445
New +$2.62M
AUTL
106
Autolus Therapeutics
AUTL
$562M
$2.42M 0.05%
422,167
– –
KNSA icon
107
Kiniksa Pharmaceuticals
KNSA
$5.93B
$2.41M 0.05%
+130,000
New +$2.66M
TCDA
108
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.26M 0.05%
427,975
– –
GRCL
109
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$1.93M 0.04%
+125,000
New +$2.95M
ORTX
110
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.86M 0.04%
25,665
– –
CRDF icon
111
Cardiff Oncology
CRDF
$77.2M
$1.39M 0.03%
150,000
– –
ARNA
112
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.39M 0.03%
20,000
– –
XFOR icon
113
X4 Pharmaceuticals
XFOR
$460M
$895K 0.02%
3,466
– –
FATE icon
114
Fate Therapeutics
FATE
$326M
$824K 0.02%
10,000
– –
IMV
115
DELISTED
IMV Inc. Common Shares
IMV
$772K 0.02%
23,437
– –
NERV icon
116
Minerva Neurosciences
NERV
$199M
$584K 0.01%
25,000
– –
CEREW
117
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$563K 0.01%
133,331
– –
OTLKW
118
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$421K 0.01%
+416,666
New +$322K
NKTR icon
119
Nektar Therapeutics
NKTR
$2.58B
$400K 0.01%
1,333
-1,334
-50% -$415K
NUVB.WS
120
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$222K ﹤0.01%
+83,332
New +$241K
CRSP icon
121
CRISPR Therapeutics
CRSP
$5.17B
– –
-200,000
Closed -$30.6M
KURA icon
122
Kura Oncology
KURA
$850M
– –
-650,000
Closed -$21.2M
QQQ icon
123
PUT
Invesco QQQ Trust
QQQ
$484B
– –
-750,000
Closed -$235M
TECX
124
Tectonic Therapeutic
TECX
$606M
– –
-20,336
Closed -$3.4M
OTIC
125
DELISTED
Otonomy, Inc.
OTIC
– –
-2,600,000
Closed -$16.8M
2 3 4
5
6

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Cormorant Asset Management held 128 positions worth $4.49B, up 6.8% from $4.2B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Cormorant Asset Management deployed $532M of net new capital in Q1 2021, opening 23 new positions and adding to 12 existing holdings. Its largest new stake was Design Therapeutics: 5,114,850 shares worth $146M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Beam Therapeutics, an estimated $71.6M trimmed.

  • Cormorant Asset Management's largest Q1 2021 buy was Design Therapeutics: 5,114,850 shares worth $146M.
  • Cormorant Asset Management added most to Turning Point Therapeutics, Inc. Common Stock in Q1 2021, an estimated $42.5M increase.
  • Cormorant Asset Management's biggest Q1 2021 reduction was Beam Therapeutics, cutting an estimated $71.6M.
  • Cormorant Asset Management fully exited Viela Bio, Inc. Common Stock in Q1 2021, selling an estimated $51.4M.
  • Cormorant Asset Management's ten largest holdings make up 51% of its $4.49B portfolio in Q1 2021.
  • Cormorant Asset Management opened 23 new positions and closed 8 in Q1 2021.
  • Cormorant Asset Management's portfolio value rose 6.8% quarter-over-quarter to $4.49B.

Based on Cormorant Asset Management's 13F filing for Q1 2021, filed 17 May 2021.